VACCINE ADJUVANT MARKET ANALYSIS

The global Vaccine Adjuvant Market was valued at US$ 1,430.0 Mn in 2021 and is forecast to reach a value of US$ 3,521.5 Mn by 2028 at a CAGR of 13.7% between 2022 and 2028. The global Vaccine Adjuvant Market is experiencing strong growth due to the rise in prevalence of infectious diseases and increasing usage of adjuvants in vaccines worldwide. Moreover, outbreak of COVID-19 (pandemic) and government initiatives or policies for immunization is expected to boost growth of the market. However, factors such as side effects & high toxicity of vaccine adjuvants and high R&D cost of developing new adjuvants are expected to hamper market growth.

Global Vaccine Adjuvant Market: Regional Insights

Based on geography, the global Vaccine Adjuvant Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period due to the growing investment in the research and development of vaccine and government recommendations/policies for immunization in the region. For instance, According to the Centers for Disease Control and Prevention (CDC), as of December 15, 2022, around 294.9 million doses of COVID-19 vaccine have been administered and reported by Federal Retail Pharmacy Program participants in the United States. This includes 8 million doses administered onsite to long-term care facilities in the early days of the COVID-19 vaccination program. The outbreak of COVID-19 increased the use of vaccine adjuvants in the U.S.

Asia Pacific is also expected to witness robust growth in the global Vaccine Adjuvant Market due to the rise in incidence of infectious diseases, increase in use of vaccine adjuvants, and government recommendations/policies for immunization in the region. For instance, India faces the challenge of a range of infectious diseases. Every fifth new tuberculosis case in the world lives in the Indian subcontinent. In 2018, the Indian Prime Minister, Narendra Modi, announced the government’s intention to make India free of TB by 2025. Prime Minister of India launched the TB Free India campaign, a plan to eliminate tuberculosis (TB) by 2025, five years ahead of the global Sustainable Development Goal (SDG) target of 2030.

Figure 1. Global Vaccine Adjuvant Market Share (%), by Region, 2021

To learn more about this report, request a free sample copy

Global Vaccine Adjuvant Market Drivers:

Increase in prevalence of infectious diseases across the globe is expected to augment growth of the global Vaccine Adjuvant Market during the forecast period. For instance, vaccination is one of the most efficient strategies for the prevention of infectious diseases. Tuberculosis (TB) is one of the world's deadliest infectious diseases, second only to COVID-19, and drug resistant TB strains are still a major concern. According to the World Health Organization (WHO), more than 1.6 million people died from TB in 2021. Worldwide, TB is the 13^th leading cause of death and the 2^nd leading infectious killer after COVID-19 (above HIV/AIDS).

Increasing use of adjuvants in vaccines around the world is expected to propel the growth of the global Vaccine Adjuvant Market over the forecast period. For instance, vaccine adjuvant are used to create stronger immune response in people receiving the vaccine and/or to enhance the immune response of vaccine. According to CDC, aluminum salts, such as aluminum phosphate, aluminum hydroxide, and aluminum potassium sulfate, have been used safely in vaccines for over 70 years. In all cases, vaccines containing adjuvants are tested for safety and effectiveness in clinical trials before they are licensed for use in the United States.

Global Vaccine Adjuvant Market Opportunities:

The outbreak of COVID-19 (pandemic) across the world is expected to provide significant growth opportunities for players in the Vaccine Adjuvant Market. For instance, with the increase in focus on the development of COVID-19 vaccines, the use of vaccine adjuvants has also increased across the globe. In July 2022, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for Novavax COVID-19 Vaccine, adjuvanted for the prevention of COVID-19 in individuals 18 years of age and older. Coronavirus disease (COVID-19) is infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Government initiatives/policies for immunization or immunization programs are expected to offer significant growth opportunities for players in the global Vaccine Adjuvant Market. For instance, immunization is one of the world’s most cost-effective public health interventions, saving millions of lives each year, and protecting children from illness & disability. The Government of India has implemented the largest immunization program worldwide, targeting more than 3 crore pregnant women and 2.6 crore children through the Universal Immunization Program (UIP). The Program will ensure that Routine Immunization (RI) services reach the unvaccinated & partially vaccinated children and pregnant women worldwide.

Global Vaccine Adjuvant Market Trends:

Adjuvants such as aluminum salts are used as additives in vaccines to enhance immune responses. Aluminum salts include such as aluminum phosphate, aluminum potassium sulfate, and aluminum hydroxide. Furthermore, aluminum-based salts are also used for research purposes to enhance the effectiveness of vaccines. This trend is expected to continue during the forecast period, driving the growth of the global Vaccine Adjuvant Market.

Moreover, with the increase in burden of infectious diseases across the world, the usage of vaccine adjuvants is also increasing with a rapid pace. The prevalence of infectious diseases worldwide is increasing rapidly due to various factors, which in turn has increased the use of vaccine adjuvants as vaccination is one of the most efficient strategies for the prevention of infectious diseases. This trend is also expected to continue over the forecast period, driving the market growth.

Global Vaccine Adjuvant Market Restraints:

Side effects and high toxicity of vaccine adjuvants expected to hinder growth of the global Vaccine Adjuvant Market. For instance, according to the CDC, adjuvanted vaccines can cause more local reactions (such as swelling, redness, and pain at injection site) and more systemic reactions (such as fever, body aches, and chills) than non-adjuvanted vaccines. The adjuvants also possess various moderate to severe side effects; in some cases, they also cause adverse events.

High R&D cost of developing new adjuvants is expected to hamper growth of the global Vaccine Adjuvant Market. For instance, vaccination has become increasingly important for the treatment of variety of chronic/infectious diseases, and thus, there has been increased R&D (research and development) for the development of new adjuvants. However, the cost of development of vaccine adjuvants is high, which is restraining the growth of the market.

Figure 2. Global Vaccine Adjuvant Market Share (%), by Type, 2021

To learn more about this report, request a free sample copy

Global Vaccine Adjuvant MarketSegmentation:

The global Vaccine Adjuvant Market report is segmented into Type, Usage, Disease Type, Application, and Geography.

Based on Type, the Vaccine Adjuvant Market is segmented into Mineral Salt-based Adjuvant, Tensoactive Adjuvants, Adjuvant Emulsions, Liposome Adjuvants, Bacteria-derived Adjuvants, Carbohydrate Adjuvants, Virus-like Particles (VLP), and Other Types. Of which, Mineral Salt-based Adjuvant Segment is expected to dominate the Vaccine Adjuvant Market over the forecast period and this is attributed to the increase in use of mineral salt-based adjuvants. Mineral salts are used as adjuvants in vaccine formulations.

Tensoactive Adjuvants Segment is also expected to witness significant growth in the near future and this is owing to the increase in usage of tensoactive adjuvants. Tensoactive adjuvants are used for the development of vaccine candidates.

Based on Usage, the market is segmented into Active Immunostimulants, Carriers, and Vehicle Adjuvants. Out of which, Active Immunostimulants Segment is expected to dominate the market over the forecast period and this is attributed to the increase in application of immunostimulants. Immunostimulants activate innate immunity and promote endogenous immune mediators such as cytokine in treating chronic infections and cancers.

Carriers Segment is also expected to witness robust growth in the near future and this is owing to the increase in use of vaccine adjuvants worldwide.

Based on Disease Type, the market is segmented into Infectious Disease and Cancer. Out of which, Infectious Disease Segment is expected to dominate the market over the forecast period and this is attributed to the increase in prevalence of infectious diseases worldwide.

Based on Application, the market is segmented into Research Applications and Commercial Applications. Out of which, Research Applications Segment is expected to dominate the market over the forecast period and this is attributed to the increase in research and development (R&D) for the development of safe and effective vaccines.

Global Vaccine Adjuvant Market: Key Developments

In May 2022, China’s National Medical Products Administration (NMPA) granted approval for GlaxoSmithKline’s (GSK) two-dose vaccine schedule, Cervarix, in girls between the ages of nine to 14 years to prevent cervical cancer. Cervarix is a recombinant, non-infectious, AS04-adjuvanted HPV bivalent (types 16, 18) vaccine.

In July 2021, Dynavax Technologies Corp. and Biological E. Limited (BE) executed a commercial supply agreement of Dynavax's CpG 1018TM advanced adjuvant for use in BE's subunit COVID- 19 vaccine candidate, CORBEVAX.

In September 2021, Novavax Inc. enrolled the first participant in its Phase 1/2 study, evaluating the safety and immunogenicity of a combination vaccine using Novavax’s seasonal influenza and COVID-19 vaccine. Clinical trial includes recombinant protein-based NVX-CoV2373 & NanoFlu vaccine candidates and patented saponin-based Matrix-M adjuvant in a single formulation.

In June 2021, Thermo Fisher Scientific entered an agreement with Moderna Inc., a biotechnology company involved in messenger RNA (mRNA) therapeutics and vaccines, for fill/finish sterile manufacturing services and supply packaging for Moderna’s COVID- 19 vaccine.

Global Vaccine Adjuvant Market: Key Companies Insights

The global Vaccine Adjuvant Market is highly competitive. This is attributed to the increase in use of vaccine adjuvants to treat variety of diseases, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global vaccine adjuvant market are Thermo Fisher Scientific Inc., Air Liquide (Seppic), Pacific GeneTech Limited, OZ Biosciences, Novavax Inc., Merck & Co. Inc., InvivoGen, GlaxoSmithKline PLC, Dynavax Technologies Corporation, CSL Limited, Croda International PLC, Vertellus, Aphios Corporation, Agenus Inc., Adjuvatis, and Associated British Foods PLC (SPI Pharma Inc.), among others.

*Definition: An adjuvant is an ingredient used in vaccines to create a stronger immune response in people receiving the vaccine. New adjuvants have been developed to target specific components of the body’s immune response, so that protection against disease is stronger and lasts longer.